



9-13-04

JFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/792,374
Filing Date: March 3, 2004
Applicant: Levy et al.
Group Art Unit: not yet assigned
Examiner: not yet assigned
Title: Classification of Patents Having Diffuse Large B-Cell
Lymphoma Based Upon Gene Expression
Attorney Docket: 9692-000042

Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant hereby submits an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS, AND OTHER INFORMATION

The patents, publications and other information requested to be considered by the Office (except unpublished U.S. patent applications) are listed on Form 1449 attached hereto.

II. COPIES

A. ____ Submitted herewith is a legible copy of (i) each U.S. patent application publication and U.S. and foreign patent; (ii) each publication or that portion which caused it to be listed; (iii) for each cross-referenced pending U.S. application listed below in Section IV, the application specification including the claims, and any drawing of the application which caused it to be listed including the claims directed to that portion; and (iv) all other information or that portion which caused it to be listed.

B. ____ Any patents, publications or other information which are listed on Form 1449 or on the copies of PTO-892, but which are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Serial Number

U.S. Filing Date

C. X Because the present application was/is being filed after June 30, 2003, no copies of the U.S. patents or U.S. patent application publications which are listed on the attached Form 1449 are enclosed pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(i). Any foreign patent documents or non-patent literature listed on the attached Form 1449 are enclosed herewith.

D. ____ This is a PCT application in the entry of the National Phase in the United States. A copy of the International Search Report is attached for the Examiner's information. The documents listed on the International Search Report are listed on the attached Form-1449 for consideration by the Examiner and for listing on any patent resulting from this application. If the International Search Report was from the US, EPO, or JPO search authorities, copies of these references should have been supplied to the USPTO under the trilateral agreement and are believed to be in the file of the above-identified application. (MPEP 1893.03(g))

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

A. X Except as may be indicated below in (B), all of the patents, publications or other information are in the English language (concise explanation not required).

B. ____ A concise explanation of the relevance of each patent, publication or other information listed that is not in the English language is as follows (see 37 C.F.R. § 1.98(a)(3)):

1. ____ See the attached foreign patent office communication from a counterpart foreign application.
2. ____ English translations are provided.
3. ____ Other:

C. ____ The following additional information is provided for the Examiner's consideration.

IV. CROSS REFERENCE TO RELATED APPLICATION(S)

A. ____ The Examiner is advised that the following co-pending application(s) contain(s) subject matter that may be related to the present application. By bringing this(these) application(s) to the Examiner's attention, Applicant(s) does(do) not waive the confidentiality provisions of 35 U.S.C. § 122.

Serial No.

Filing Date

Art Unit

V. THIS IDS IS BEING FILED UNDER

A. X **37 C.F.R. § 1.97(b):** (check only one box)

1. ____ within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. § 1.97(b)(1)). No fee or certification is required.

2. ____ within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b)(2)). No fee or certification is required.

3. X before the mailing of a first Office Action on the merits (37 C.F.R. § 1.97(b)(3)). No fee or certification is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97(c) and see the certification under 37 C.F.R. § 1.97(e) below; or, if no certification has been made, charge our deposit account a fee in the amount of \$180.00 as required by 37 C.F.R. § 1.17(p).

4. ____ before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No fee or certification is required.

B. ____ **37 C.F.R. § 1.97(c):** (check only one box)

before the mailing date of either any Final Office Action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution.

1. ____ No certification; therefore, a fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

2. ____ See the certification below. No fee is required.

C. ____ **37 C.F.R. § 1.97(d):**

after the mailing date of either a Final Office Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311, yet on or before payment of the issue fee.

1. ____ See the certification below. A fee in the amount of \$180.00 is required by 37 C.F.R. § 1.17(p).

VI. **CERTIFICATION UNDER 37 C.F.R. § 1.97(e):** (check only one box)

The undersigned hereby certifies that:

A. ____ each item of information contained in this IDS was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(1)). See further statement under 37 C.F.R. § 1.704(d) below in section VII, if applicable; or

B. ____ no item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS (See 37 C.F.R. § 1.97(e)(2)).

C. ____ Some of the items of information were first cited in a communication from a foreign patent office. As to this information, the undersigned hereby certifies that each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this IDS.

VII. STATEMENT UNDER 37 CFR 1.704(d)

The undersigned hereby states that:

____ each item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this IDS.

VIII. PAYMENT OF FEES (check only one box)

A. ____ A check in the amount of \$180.00 is enclosed for the above-identified fee.

B. ____ Please charge Deposit Account No. 08-0750 in the amount of \$180.00 for the above-indicated fee. A duplicate copy of this paper is attached.


The above references are being cited only in the interest of candor and without any admission that they constitute statutory prior art, contain matter which anticipates the invention, or which would render the same obvious, either singly or in combination, to a person of ordinary skill in the art. Furthermore, this Information Disclosure Statement shall not be construed as a representation that a search has been made.

If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 08-0750.

Please charge any additional fees or credit any overpayment pursuant to 37 C.F.R. § 1.16 or § 1.17 to Deposit Account No. 08-0750.

Respectfully submitted,

Dated: Sept 10, 2004

By: 
David L. Suter
Reg. No. 30,692
Michael J. Lang, Ph.D.
Reg. No. 51,120

HARNESS, DICKEY & PIERCE, P.L.C.
P.O. Box 828
Bloomfield Hills, Michigan 48303
(248) 641-1600
MLF/MJL/csd

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/792,374
	Filing Date	March 3, 2004
	First Named Inventor	Levy et al.
	Art Unit	not yet assigned
	Examiner Name	not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number	9692-000042

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449; copies of 39 other documents; and return postcard.
Remarks The Commissioner is hereby authorized to charge any additional fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 08-0750. A duplicate copy of this sheet is enclosed.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Harness, Dickey & Pierce, P.L.C.	Attorney Name Michael J. Lang	Reg. No. 51,120
Signature			
Date	Sept 10, 2004		

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Michael J. Lang	Express Mail Label No.	EV 531 989 889 US (9/10/2004)
Signature		Date	Sept 10, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 531 989 889 US



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/792,374
	Filing Date	March 3, 2004
	First Named Inventor	Levy et al.
	Art Unit	not yet assigned
	Examiner Name	not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number	9692-000042


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC) <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449; copies of 39 other documents; and return postcard.
Remarks		The Commissioner is hereby authorized to charge any additional fees that may be required under 37 CFR 1.16 or 1.17 to Deposit Account No. 08-0750. A duplicate copy of this sheet is enclosed.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm or Individual name	Harness, Dickey & Pierce, P.L.C.	Attorney Name Michael J. Lang	Reg. No. 51,120
Signature			
Date	Sept 10, 2004		

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Michael J. Lang	Express Mail Label No.	EV 531 989 889 US (9/10/2004)
Signature		Date	Sept 10, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

Sheet 1 of 4

ATTORNEY DOCKET No.	SERIAL No.
9692-000042/US	10/792,374
APPLICANT	
Levy, et al.	
FILING DATE	GROUP
March 3, 2004	Unknown

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig.	Examiner's Initials	
1.		Adida et al., <i>Prognostic significance of surviving expression in diffuse large B-cell lymphomas</i> , Blood, Vol. 96, No. 5, pp 1921-1925, 2000
2.		Alizedeh et al., <i>Distinct Types of Diffuse Large B-cell Lymphoma Identified by Gene Expression Profiling</i> , Nature, Vol. 403, pp 503-511, 2000
3.		Barrans et al., <i>Germinal center phenotype and bcl1-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma</i> , Blood, Vol. 99, No. 4, pp 1136-1143, 2002
4.		Boehm et al., <i>The rhombotin family of cysteine-rich LIM-domain oncogenes: Distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13</i> , Proc. Natl. Acad. Sci. U S A, Vol. 88, No. 10, pp 4367-4371, 1991
5.		Cattoretti et al., <i>BCL-6 Protein Is Expressed in Germinal-Center B Cells</i> , Blood, Vol. 86, No. 1, pp 45-53, 1995
6.		Chang et al., <i>BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor</i> , Proc. Natl. Acad. Sci. U S A, Vol. 93, pp 6947-6952, 1996
7.		Dent et al., <i>T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6</i> , Proc. Natl. Acad. Sci. U S A, Vol. 95, pp 13823-13828, 1998
8.		Freeman et al., <i>Quantitative RT-PCR: Pitfalls and Potential</i> , BioTechniques, Vol. 26, No. 1, pp 112-125, 1999

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 2 of 4</p>	ATTORNEY DOCKET NO.	SERIAL No.
	9692-000042/US	10/792,374
	APPLICANT	
	Levy, et al.	
	FILING DATE	GROUP
	March 3, 2004	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
9.		Gascoyne et al., <i>Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma</i> , Blood, Vol. 90, No. 1, pp 244-251, 1997
10.		Harris et al., <i>A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group</i> , Blood, Vol. 84, No. 5, pp 1361-1392, 1994
11.		Hermine et al., <i>Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma</i> , Blood, Vol. 87, No. 1, pp 265-272, 1996
12.		Hill et al., <i>Prognostic Significance of BCL-2 Expression and bcl-2 Major Breakpoint Region Rearrangement in Diffuse Large Cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation Study</i> , Blood, Vol. 88, No. 3, pp 1046-1051, 1996
13.		Ichikawa et al., <i>Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma</i> , New England J Med, Vol. 337, No. 8, pp 529-534, 1997
14.		Kaiser, <i>Seeking the Cause of Induced Leukemias in X-SCID Trial</i> , Science, Vol. 299, p 495, 2003
15.		Kerckaert et al., <i>LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas</i> , Nat. Genet, Vol. 5, pp 66-70, 1993
16.		Koduru et al., <i>Correlation Between Mutation in P53, p53 Expression, Cytogenetics, Histologic Type, and Survival in Patients With B-Cell Non-Hodgkin's Lymphoma</i> , Blood, Vol. 90, No. 10, pp 4078-4091, 1997
17.		Kramer et al., <i>Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma</i> , Blood, Vol. 92, No. 9, pp 3152-3162, 1998
18.		Kramer et al., <i>Clinical Significance of bcl2 and p53 Protein Expression in Diffuse Large B-Cell Lymphoma: A Population-Based Study</i> , J. Clin Onco, Vol. 14, No. 7, pp 2131-2138, 1996
19.		Krenacs et al., <i>Transcription Factor B-Cell-Specific Activator Protein (BSAP) Is Differentially Expressed in B Cells and in Subsets of B-Cell Lymphomas</i> , Blood, Vol. 92, No. 4, pp 1308-1316, 1998
20.		Livak et al., <i>Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2^{-ΔΔCT} Method</i> , Methods, Vol. 25, pp 402-408, 2001
21.		Lossos et al., <i>HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma</i> , Blood, Vol. 101, No. 2, pp 433-440, 2003

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 3 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	9692-000042/US	10/792,374
	APPLICANT	
	Levy, et al.	
	FILING DATE	GROUP
	March 3, 2004	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
22.		Lossos et al., <i>Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma</i> , Blood, Vol. 98, No. 4, pp 945-951, 2001
23.		Lossos et al., <i>Diffuse Large B-Cell Lymphoma: Insights Gained from Gene Expression Profiling</i> , Int. J. Hematol., Vol. 77, pp 321-329, 2003
24.		Lossos et al., <i>Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies</i> , Leukemia, Vol. 17, pp 789-795, 2003
25.		Miller et al., <i>Prognostic Significance of the Ki-67-Associated Proliferative Antigen in Aggressive Non-Hodgkin's Lymphomas: A Prospective Southwest Oncology Group Trial</i> , Blood, Vol. 83, No. 6, pp 1460-1466, 1994
26.		Pfaffl et al., <i>Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR</i> , Nucleic Acid Research, Vol. 30, No. 9, e36, pp 1-10, 2002
27.		Royer-Pokora et al., <i>TTG-2, a new gene encoding a cystein-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14) (p13;q11) Oncogene</i> , Vol. 6, pp 1887-1893, 1993
28.		Proost et al., <i>The Role of Chemokines in Inflammation</i> , Int. J. Clin. Lab. Res., Vol. 26, pp 211-223, 1996
29.		Rosenwald et al., <i>The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-Cell lymphoma</i> , N. Engl. J. Med., Vol. 346, No. 25, pp 1937-1947, 2002
30.		Seyfert et al., <i>Transcriptional repression by the proto-oncogene BCL-6</i> , Oncogene, Vol. 12, pp 2331-2342, 1996
31.		Shaffer et al., <i>BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle Control</i> , Immunity, Vol. 13, pp 199-212, 2000
32.		Shipp et al., <i>Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning</i> , Nat. Med., Vol. 8, No. 1, pp 68-74, 2002
33.		Terol et al., <i>Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome</i> , Ann Oncol, Vol. 14, pp 467-474, 2003
34.		Shipp et al., <i>A Predictive Model For Aggressive Non-Hodgkin's Lymphoma</i> , The International Non-Hodgkin's Lymphoma Prognostic Factors Project, New England Journal Med., Vol. 329, No. 14, pp 987-994, 1993

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION</p> <p>(Use several sheets if necessary)</p> <p>Sheet 4 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	9692-000042/US	10/792,374
	APPLICANT	
	Levy, et al.	
	FILING DATE	GROUP
	March 3, 2004	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
35.		The Non-Hodgkin's Lymphoma classification Project, <i>A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma</i> , Blood, Vol. 89, No. 11, pp 3909-3918, 1997
36.		Tusher et al., <i>Significance analysis of microarrays applied to the ionizing radiation response</i> , Proc. Natl. Acad. Sci. U S A, Vol. 98, No. 9, pp 5116-5121, 2001
37.		Warren et al., <i>The Oncogenic Cysteine-Rich LIM Domain Protein Rbtl2 Is Essential for Erythroid Development</i> , Cell, Vol. 78, pp 45-57, 1994
38.		Yamada et al., <i>The oncogenic LIM-only transcription factor Lmo2 regulates angiogenesis but not vasculogenesis in mice</i> , Proc. Natl. Acad. Sci. U S A, Vol. 97, No. 1, pp 320-324, 2000
39.		Ye et al., <i>The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation</i> , Nat. Genet., Vol. 16, pp 161-170, 1997

Examiner:	Date Considered:
-----------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.